Intech Biopharm Ltd
Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and COPD; and dry powder inhaler, a product comprises of blisters and capsules. The company offers its products under the SYN006, SYN010, SYN007, Synflutide… Read more
Intech Biopharm Ltd (6461) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.125x
Based on the latest financial reports, Intech Biopharm Ltd (6461) has a cash flow conversion efficiency ratio of -0.125x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-123.21 Million) by net assets (NT$987.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Intech Biopharm Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Intech Biopharm Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Intech Biopharm Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Intech Biopharm Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
REFINE Co. Ltd.
KQ:377450
|
0.020x |
|
Binh Duong Trade and Development JSC
VN:TDC
|
0.212x |
|
First Seacoast Bancorp
NASDAQ:FSEA
|
0.010x |
|
Siebert Financial Corp
NASDAQ:SIEB
|
0.525x |
|
DANIEL THWAITES LS-25
F:7KW
|
N/A |
|
Japan Medical Dynamic Marketing INC
F:JMD
|
N/A |
|
Mega Or
TA:MGOR
|
0.015x |
|
Remed Co.Ltd
KQ:302550
|
-0.007x |
Annual Cash Flow Conversion Efficiency for Intech Biopharm Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Intech Biopharm Ltd from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$814.28 Million | NT$-269.22 Million | -0.331x | -89.15% |
| 2023-12-31 | NT$1.17 Billion | NT$-204.13 Million | -0.175x | +5.28% |
| 2022-12-31 | NT$1.03 Billion | NT$-190.39 Million | -0.185x | -23.05% |
| 2021-12-31 | NT$1.34 Billion | NT$-200.61 Million | -0.150x | -19.06% |
| 2020-12-31 | NT$1.33 Billion | NT$-167.38 Million | -0.126x | -4.52% |
| 2019-12-31 | NT$1.57 Billion | NT$-189.09 Million | -0.121x | +22.84% |
| 2018-12-31 | NT$1.49 Billion | NT$-232.43 Million | -0.156x | -45.69% |
| 2017-12-31 | NT$1.36 Billion | NT$-145.29 Million | -0.107x | -- |